WO2000078335A1 - Compositions pour la liberation regulee de l'hormone gnrh et ses analogues - Google Patents
Compositions pour la liberation regulee de l'hormone gnrh et ses analogues Download PDFInfo
- Publication number
- WO2000078335A1 WO2000078335A1 PCT/US2000/013615 US0013615W WO0078335A1 WO 2000078335 A1 WO2000078335 A1 WO 2000078335A1 US 0013615 W US0013615 W US 0013615W WO 0078335 A1 WO0078335 A1 WO 0078335A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- deslorelin
- gnrh
- saib
- analogs
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 168
- 238000013270 controlled release Methods 0.000 title claims abstract description 14
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 title claims description 52
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 title claims description 48
- 229940088597 hormone Drugs 0.000 title description 6
- 239000005556 hormone Substances 0.000 title description 5
- 230000016087 ovulation Effects 0.000 claims abstract description 42
- 239000007788 liquid Substances 0.000 claims abstract description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000000556 agonist Substances 0.000 claims abstract description 19
- 241001465754 Metazoa Species 0.000 claims abstract description 15
- 230000001850 reproductive effect Effects 0.000 claims abstract description 14
- 239000012876 carrier material Substances 0.000 claims abstract description 10
- 241000251468 Actinopterygii Species 0.000 claims abstract description 5
- 230000004962 physiological condition Effects 0.000 claims abstract description 5
- 235000015170 shellfish Nutrition 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 134
- 108700025485 deslorelin Proteins 0.000 claims description 88
- UVGUPMLLGBCFEJ-SWTLDUCYSA-N sucrose acetate isobutyrate Chemical compound CC(C)C(=O)O[C@H]1[C@H](OC(=O)C(C)C)[C@@H](COC(=O)C(C)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@@H](COC(C)=O)O1 UVGUPMLLGBCFEJ-SWTLDUCYSA-N 0.000 claims description 79
- 239000001797 sucrose acetate isobutyrate Substances 0.000 claims description 79
- 235000010983 sucrose acetate isobutyrate Nutrition 0.000 claims description 79
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 claims description 51
- 229960005408 deslorelin Drugs 0.000 claims description 50
- 239000002904 solvent Substances 0.000 claims description 43
- LYCYLGFSIXIXAB-NUZRHMIVSA-N acetic acid;(2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(2s)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-h Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 LYCYLGFSIXIXAB-NUZRHMIVSA-N 0.000 claims description 39
- 229960004165 deslorelin acetate Drugs 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 27
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 26
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims description 21
- 241000124008 Mammalia Species 0.000 claims description 19
- 244000309465 heifer Species 0.000 claims description 18
- 241000283690 Bos taurus Species 0.000 claims description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 11
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 claims description 8
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 8
- -1 N-methylpynolidone Chemical compound 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims description 5
- 102100024028 Progonadoliberin-1 Human genes 0.000 claims description 5
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims description 5
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims description 5
- HJNZCKLMRAOTMA-BRBGIFQRSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(2s)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(2-methyl-1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydr Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=C(C)NC2=CC=CC=C12 HJNZCKLMRAOTMA-BRBGIFQRSA-N 0.000 claims description 4
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 claims description 4
- 108010000817 Leuprolide Proteins 0.000 claims description 4
- 229950010887 avorelin Drugs 0.000 claims description 4
- 229940116333 ethyl lactate Drugs 0.000 claims description 4
- 239000001087 glyceryl triacetate Substances 0.000 claims description 4
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 4
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 4
- 229960004338 leuprorelin Drugs 0.000 claims description 4
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 4
- 229960002622 triacetin Drugs 0.000 claims description 4
- 235000019439 ethyl acetate Nutrition 0.000 claims description 3
- 210000004994 reproductive system Anatomy 0.000 claims description 3
- 244000144972 livestock Species 0.000 abstract description 3
- 239000003488 releasing hormone Substances 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 description 58
- 238000011282 treatment Methods 0.000 description 55
- 102000009151 Luteinizing Hormone Human genes 0.000 description 31
- 108010073521 Luteinizing Hormone Proteins 0.000 description 31
- 229940040129 luteinizing hormone Drugs 0.000 description 30
- 239000000243 solution Substances 0.000 description 22
- 238000002347 injection Methods 0.000 description 21
- 239000007924 injection Substances 0.000 description 21
- 239000000654 additive Substances 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000012173 estrus Effects 0.000 description 10
- 238000002604 ultrasonography Methods 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 238000007865 diluting Methods 0.000 description 8
- 238000007726 management method Methods 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 230000001817 pituitary effect Effects 0.000 description 5
- 238000003127 radioimmunoassay Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 244000144980 herd Species 0.000 description 4
- 230000009027 insemination Effects 0.000 description 4
- 230000000624 ovulatory effect Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000001158 estrous effect Effects 0.000 description 3
- 239000013020 final formulation Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108010037003 Buserelin Proteins 0.000 description 2
- 101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010069236 Goserelin Proteins 0.000 description 2
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
- 206010022095 Injection Site reaction Diseases 0.000 description 2
- 206010053425 Injection site swelling Diseases 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 2
- 229960002719 buserelin Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 2
- 229950002007 estradiol benzoate Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 108700020627 fertirelin Proteins 0.000 description 2
- 229950001491 fertirelin Drugs 0.000 description 2
- DGCPIBPDYFLAAX-YTAGXALCSA-N fertirelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 DGCPIBPDYFLAAX-YTAGXALCSA-N 0.000 description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
- 229960002913 goserelin Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 208000006155 precocious puberty Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 2
- 229960004824 triptorelin Drugs 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000283482 Alloteropsis cimicina Species 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 244000052363 Cynodon dactylon Species 0.000 description 1
- 235000017898 Digitaria ciliaris Nutrition 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- OTGQIQQTPXJQRG-UHFFFAOYSA-N N-(octadecanoyl)ethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCO OTGQIQQTPXJQRG-UHFFFAOYSA-N 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 238000010266 Sephadex chromatography Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 229940116342 acetylated sucrose distearate Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 150000001719 carbohydrate derivatives Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000008217 follicular development Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical class OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical group CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940090213 lutalyse Drugs 0.000 description 1
- 230000000938 luteal effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- RKISUIUJZGSLEV-UHFFFAOYSA-N n-[2-(octadecanoylamino)ethyl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCNC(=O)CCCCCCCCCCCCCCCCC RKISUIUJZGSLEV-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000010517 refined sesame oil Substances 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960001479 tosylchloramide sodium Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Definitions
- GnRH or its analogs or agonists can be used to treat conditions related to the reproductive system. Examples include precocious puberty in children, endometriosis in women, prostate cancer in men, and other conditions requiring or responding to short term or long term GnRH therapy.
- the selection of an appropriate drug delivery system should be based on the pharmacokinetic and pharmacodynamic properties of the drug.
- the importance of the pharmacodynamic properties of a drug is especially relevant in the case of hormones that target specific high affinity receptors to produce their effect. In the case of GnRH this relationship is dependent on multiple elements including species, reproductive status and complex concentration presentation effects of the peptide and pituitary responsiveness to it.
- compositions are suitable for controlled release of GnRH, its analogs, and/or its agonists, particularly for the purpose of treating conditions relating to the reproductive system in a variety of species.
- the composition of the present invention can be used for advancing ovulation in domesticated animals, in particular in female mammals, and even more particularly, in mares, gilts, sows, ewes, cows, heifers, she-goats, and the like.
- the composition includes
- the composition includes a system based on sucrose acetate isobutyrate (SAIB) a fully-esterified sucrose molecule.
- SAIB sucrose acetate isobutyrate
- SAIB is a low molecular weight material that has many of properties associated with polymeric materials. Because SAIB is a non-polymer, dilution with only small amounts of solvents are required to give an easily-injectable solution.
- the SAIB drug delivery system technology suitable for treating reproductive disorders susceptible to treatment by GnRH, in particular for inducing ovulation, in animals, and in particular in female mammals, e.g., mares, gilts and sows, ewes, cows, heifers, she-goats, and the like, with a composition that is injectable and sterilizable.
- the composition releases the GnRH or its analog or agonist over a relatively short time period, typically about 1 to about 12 hours, more particularly about 1 to about 6 hours.
- non-polymeric, non- water soluble liquid carrier material, GnRH, or its analog or agonist, and solvent can be formulated as a solution or suspension of the GnRH in the solvent.
- Suspensions can be formed by, e.g., using a solvent in which GnRH, its analog or agonist is insoluble. Increased stability has been found to result from the use of a suspension.
- the composition can include additives that can substantially lengthen the delivery time up to several months, more particularly from about 1 to about 30 days, even more particularly from about 14 to about 30 days, thereby making the composition suitable for induction of cyclicity or ovulation in seasonally nonovulatory animals, such as mares, or for treatment of conditions susceptible to long term therapy with GnRH, or analogs or agonists thereof, such as precocious puberty in human children, endometriosis in women, and prostate cancer in men, and for inducing spawning in marine life, such as finned fish or shellfish.
- additives that can substantially lengthen the delivery time up to several months, more particularly from about 1 to about 30 days, even more particularly from about 14 to about 30 days, thereby making the composition suitable for induction of cyclicity or ovulation in seasonally nonovulatory animals, such as mares, or for treatment of conditions susceptible to long term therapy with GnRH, or analogs or agonists thereof, such as precocious puberty
- the invention relates to methods of treating reproductive disorders in animals by administering to an animal in need thereof an effective amount of the composition described above, i.e., a combination of non- polymeric, non-water soluble liquid carrier material and GnRH, or its analogs or agonists.
- the invention relates to methods of inducing ovulation in a female mammal by administering to the female mammal an effective amount of the composition described above, i.e., a combination of non-polymeric, non- water soluble liquid carrier material and GnRH, or its analogs or agonists.
- the female mammal may be a sow, gilt, cow, or heifer.
- GnRH Gonodotropin releasing hormone also known as LH-RH or LHRH
- FIGURE 1 shows LH concentrations in mares following treatment with experimental formulations.
- Figure 2 shows deslorelin acetate concentrations in gilts following treatment with a formulation according to the invention.
- Figure 3 shows the LH concentrations in gilts following treatment with a formulation according to the invention.
- Figure 4 shows the LH levels in heifers following treatment with a formulation according to the invention.
- the present invention relates to a composition for the controlled release of GnRH or analogs or agonists thereof in animals, in particular in female mammals, and even more particularly, in domesticated female mammals, such as mares, gilts, and sows, cows, heifers, ewes, she-goats, bitches, cats, and the like to induce ovulation, comprising:
- the non- water soluble liquid canier material is sucrose acetate isobutyrate. In another embodiment of the composition of the present invention, the non- water soluble liquid canier material is present in an amount from about 99. 5 percent to about 10 percent by weight, relative to the total weight of the composition. In another embodiment of the composition of the present invention, the non- water soluble liquid canier material is present in an amount from about 95 percent to about 25 percent by weight, relative to the total weight of the composition.
- the composition further comprises a solvent in which the non-water soluble liquid canier is soluble.
- the solvent is selected from the group consisting of ethanol, dimethylsulfoxide, ethyl lactate, ethyl acetate, benzyl alcohol, triacetin, N-methylpynolidone, propylene carbonate, and glycofurol.
- the solvent may be one in which the GnRH, its analog or agonist, is insoluble, resulting in a suspension.
- the solvent is propylene carbonate.
- the GnRH, analog, or agonist may desirably be deslorelin, which is insoluble in propylene carbonate. The resulting composition forms a suspension.
- the solvent is present in an amount from about 10 to about 50 percent by weight, relative to the weight of the composition.
- the analog is deslorelin.
- the analog is selected from deslorelin, avorelin, leuprolide, and natural LHRH.
- the present invention also relates to a liquid composition for the controlled release of GnRH or analogs thereof in mares to induce ovulation, comprising sucrose acetate isobutyrate and ethanol in a weight ratio of between about 75:25 and about 60:40, and GnRH or analog thereof or combination thereof in a concentration of between about 0.1 to about 5.0 mg/ml of liquid composition, to provide a dose of between about 0.3 mg and about 10 mg of GnRH or analog thereof or combination thereof.
- the present invention also relates to a liquid composition for the controlled release of GnRH or analogs thereof in mares to induce ovulation, comprising sucrose acetate isobutyrate and ethanol in a weight ratio of between about 75:25 and about 60:40, and GnRH or analog thereof or combination thereof in a concentration of between about 1.0 to about 2.5 mg/ml of liquid composition, to deliver a dose of between about 0.3 mg and about 10 mg of GnRH or analog thereof or combination thereof.
- the analog of GnRH is deslorelin.
- the composition is sterilized before administration to mares.
- composition is filter sterilized before administration to mares.
- the present invention also relates to a filter sterilized liquid composition for the controlled release of deslorelin in mares to induce ovulation, comprising sucrose acetate isobutyrate and ethanol in a weight to weight ratio of about 75:25, and deslorelin at a concentration of between about 0.1 and about 5.0 mg / ml of liquid composition, to deliver a dose between about 1 mg and about 2 mg of deslorelin, said composition administrable by injection.
- the present invention also relates to a filter sterilized liquid composition for the controlled release of deslorelin in mares to induce ovulation, comprising sucrose acetate isobutyrate and ethanol in a weight to weight ratio of about 75:25, and deslorelin at a concentration of between about 1.0 and about 2.5 mg / ml of liquid composition, to deliver a dose between about 1 mg and about 2 mg of deslorelin, said composition administrable by injection.
- the present invention also relates to a liquid composition, for the controlled release of deslorelin in gilts, sows, heifers, and cows to induce ovulation, comprising sucrose acetate isobutyrate and propylene carbonate in a weight ratio of about 70:30 and containing deslorelin acetate at a concentration about 25 ⁇ g/ml of liquid composition, to deliver a dose between about 12.5 and about 100 ⁇ g of deslorelin acetate, said composition adminstrable by injection.
- smaller doses of deslorelin acetate may be administered using, e.g., a concentration of about 12.5 ⁇ g/ml to achieve dosages of about 1 ⁇ g to about 12.5 ⁇ g.
- dosages of between 1 ⁇ g and about 100 ⁇ g are administered, more particularly between about 6.25 ⁇ g and about 25 ⁇ g, even more particularly between about 6.25 ⁇ g and about 12.5 ⁇ g.
- the composition can be used in methods for inducing spawning in marine animals, such as finned fish or shellfish.
- HVLCM High Viscosity Liquid Carrier Material
- a high viscosity liquid canier material should be selected that is non- polymeric, non-water soluble, and has a viscosity of at least 5,000 cP, (and optionally at least 10,000, 15,000; 20,000; 25,000 or even 50,000 cP) at 37°C, and that does not crystallize neat under ambient or physiological conditions.
- non- water soluble refers to a material that is soluble in water to a degree of less than one percent by weight under ambient conditions.
- Suitable canier materials are disclosed in U.S. Patent No. 5,747,058, the entire contents of which are hereby incorporated by reference.
- the HVLCM significantly decreases in viscosity when mixed with a solvent to form a LVLCM that can be mixed with a substrate for controlled delivery.
- the LVLCM/substrate composition is typically easier to place in the body than a HVLCM/substrate composition, because it flows more easily into and out of syringes or other implantation means, and can easily be formulated as an emulsion.
- the LVLCM can have any desired viscosity. It has been found that a viscosity range for the LVLCM of less than approximately 1000 cP, and more particularly less than 200 cP, is typically useful for in vivo applications.
- sucrose acetate isobutyrate (SAIB)
- HVLCM sucrose acetate isobutyrate
- SAIB is orally non-toxic and is cunently used to stabilize emulsions in the food industry. It is a very viscous liquid and has an unusual property that there is a dramatic change in viscosity with small additions of heat or with the addition of solvents. It is soluble in a large number of biocompatible solvents. When in solution or in an emulsion, SAIB can be applied via injection.
- the HVLCM can be stearate esters such as those of propylene glycol, glyceryl, diethylaminoethyl, and glycol, stearate amides and other long-chain fatty acid amides, such as N,N'-ethylene distearamide, stearamide MEA and DEA, ethylene bistearamide, cocoamine oxide, long-chain fatty alcohols, such as cetyl alcohol and stearyl alcohol, long-chain esters such as myristyl myristate, beheny erucate, and glyceryl phosphates.
- stearate esters such as those of propylene glycol, glyceryl, diethylaminoethyl, and glycol
- stearate amides and other long-chain fatty acid amides such as N,N'-ethylene distearamide, stearamide MEA and DEA, ethylene bistearamide, cocoamine oxide
- long-chain fatty alcohols such as
- the HVLCM is acetylated sucrose distearate (Crodesta A- 10)
- the HVLCM is present in the composition in any amount that achieves the desired affect.
- the HVLCM is typically present in controlled delivery compositions for GnRH or its analogs in an amount in the range from about 99.5 percent to about 10 percent by weight, more typically, between about 90 and about 25 percent, and most typically, between about 85 and about 65 percent, relative to the total weight of the composition.
- Suitable analogs of gonodotrophlin releasing hormone are suitable for controlled release in the compositions of the present invention. Suitable analogs include, but are not limited to those listed in the following Table I. TABLE I
- Prefened GnRH analogs include deslorelin, avorelin, leuprolide, and natural LHRH.
- GnRH analogs Another series of prefened GnRH analogs includes triptorelin, nafarelin, goserelin, buserelin, and fertirelin. Most prefened is deslorelin.
- the GnRH analogs are synthesized by any of a variety of conventional techniques. See generally Menifield, B., Science 232:342 (1986), Norman, A.W. et al., Hormones Academic Press New York 1987. Deslorelin is synthesized by the method of Ajayaghosh, A. et al., J. Org. Chem. 55:2826(1990); Nestor, J.J. et al.,
- the composition When the composition is used as a LVLCM, it should contain a solvent in which the HVLCM is soluble.
- the substance to be delivered may also soluble in the solvent, however, increased stability of the composition may be obtained by forming a suspension of the substance to be delivered in the solvent.
- increased stability has been obtained where the substance to be delivered is deslorelin by using propylene carbonate as the solvent, thereby forming a suspension of the deslorelin therein.
- the solvent should be non-toxic, water soluble or water miscible, and otherwise biocompatible. Solvents that are toxic should not be used for pharmaceutical or agricultural purposes.
- the solvents used to inject the composition into animals should not cause significant tissue initation or necrosis at the site of implantation.
- the solvent should be at least water soluble, so that it will diffuse quickly into bodily fluids or other aqueous environment, causing the composition to coagulate or solidify.
- suitable solvents include ethanol, ethyl lactate, propylene carbonate, glycofurol, N-methylpynolidone, 2 pynolidone, propylene glycol, acetone, methyl acetate, ethyl acetate, methyl ethyl ketone, benzyl alcohol, triacetin, dimethylformamide, dimethylsulfoxide, tetrahydrofuran, caprolactam, decylmethylsulfoxide, oleic acid, and l-dodecylazacycloheptan-2-one.
- a prefened solvent is propylene carbonate.
- the prefened solvents are ethanol, dimethylsulfoxide, ethyl lactate, ethyl acetate, benzyl alcohol, triacetin, N- methylpynolidone, propylene carbonate, and glycofurol.
- SAIB is not miscible with glycerol, corn oil, peanut oil, 1 ,2-propanediol, polyethylene glycol (PEG200), super refined sesame oil, and super refined peanut oil. Accordingly, the latter group of solvents are not prefened for use with SAIB.
- the solvent is typically added to the compositions in an amount in the range from about 5 percent to about 55 percent by weight, relative to the total weight of the composition.
- the solvent is present in the composition in an amount in the range from about 10 percent to about 50 percent by weight.
- Another prefened range is from about 10 percent to 30 percent by weight.
- the delivery characteristics of the composition can be varied by adding one or more optional additives to the composition.
- additives include those disclosed in U.S. Patent No. 5,747,058, the entire contents of which are incorporated herein by reference.
- suitable additives include biodegradeable polymers, non-biodegradeable polymers, natural oils, synthetic oils, carbohydrates or carbohydrate derivatives, inorganic salts, BSA (bovine serum albumin), surfactants, organic compounds, such as sugars, and organic salts, such as sodium citrate.
- BSA bovine serum albumin
- surfactants organic compounds, such as sugars, and organic salts, such as sodium citrate.
- organic compounds such as sugars
- organic salts such as sodium citrate.
- additives can also be used to lengthen the delivery time for the active ingredient (i.e., GnRH, its analogs or agonists), making the composition suitable for treatment of disorders or conditions responsive to longer term GnRH administration, as described above.
- Suitable additives in this regard include those disclosed in U.S. Patent No. 5,747,058.
- suitable additives for this purpose include polymeric additives, such as cellulosic polymers and biodegradeable polymers.
- suitable cellulosic polymers include cellulose acetates, cellulose ethers, and cellulose acetate butyrates.
- Suitable biodegradeable polymers include polylactic acid, polyglycolic acid, and copolymers thereof.
- Additives, when present, are generally included in an amount ranging from about 0.02 wt% to about 20 wt%, more particularly from about 1 wt% to about 20 wt% based on the total weight of the composition.
- compositions described herein can be administered to the host through a variety of methods which can vary depending on the result to be achieved.
- the composition can be administered, for example, topically, systematically (for example, mucosally (orally, rectally, vaginally, or nasally), or parenterally (intravenously, subcutaneously, intramuscularly, or intraperitoneally) in an appropriate canier, if desired.
- Suitable hosts include female mammals, such as livestock or pet mammals, such as mares, gilts, sows, ewes, she-goats, cows, bitches, and the like.
- the present compositions are administered as solutions or suspensions via injection.
- the small amount of solvent used in the composition leaches into the aqueous fluid of the host, forming a highly viscous depot for the controlled delivery of substances. See, for example, Ansel, H.C. et al., Pharmaceutical Dosage Forms and Drug Del. Systems, sixth ed., 1995.
- a solution of deslorelin in DMSO (1.0 wt. %) was prepared.
- a predetermined amount (2.1870 g) of deslorelin acetate (DA)/DMSO was added to 7.9230 g of the 95:5 SAIB:DMSO solution.
- the final formulation contained 2.4 mg/mL deslorelin and had an SAIB:DMSO ratio of 75:25.
- a solution of deslorelin in ethanol (2.1 wt.%) was prepared.
- a concentrated solution of 95:5 weight ratio SAIB:ethanol was also prepared.
- a predetermined amount (1.0376 g) of deslorelin acetate/ethanol was added to 8.9917 g of the 95:5 SAIB:ethanol solution.
- the final formulation contained 2.3 mg/mL deslorelin and had an SAIB:ethanol ratio of 85:15.
- a solution of deslorelin in ethanol (1.9 wt.%) was prepared.
- a concentrated solution of 95:5 weight ratio SAIB:ethanol was also prepared.
- a predetermined amount (1.0826 g) of deslorelin acetate/ethanol was added to 7.9085 g of the 95:5 SAIB:ethanol solution.
- the final formulation contained 2.2 mg/mL deslorelin and had an SAIB:ethanol ratio of 75:25.
- a dose titration study was performed using this 75:25 SAIB:ethanol formulation that evaluated deslorelin concentrations of 0.5, 1.0, 1.5, and 2.0 mg/mL.
- a concentrated solution of SAIB in ethanol (83.6 wt. %) was prepared and sterile filtered using a 0.2 ⁇ m hydrophobic filter. Pure ethanol and a solution of deslorelin in ethanol (21.0 mg/g) were sterile filtered using 0.22 ⁇ m sterile syringe filters.
- a dose titration study was also performed using a 65:35 SAIB:ethanol formulation that evaluated deslorelin concentrations of 0.5, 1.0, 1.5, and 2.0 mg/mL.
- a concentrated solution of SAIB in ethanol (83.6 wt. %) was prepared and sterile filtered using a 0.2 ⁇ m hydrophobic filter. Pure ethanol and a solution of deslorelin in ethanol (21.0 mg/g) were sterile filtered using 0.22 ⁇ m sterile syringe filters.
- Agricultural Center Horse Farm and were all of light horse type, mainly Quarter Horses, Thoroughbreds and Arabians. All mares were in good body condition and were maintained on native summer grass pasture (predominantly bermuda grass). The majority of mares in the herd were not bred the previous season, whereas six had foaled within 30 days and were lactating. The mares were placed on a daily regimen of estrous detection beginning June 1 , and were all administered a general health and reproductive soundness exam during June. Only mares with good health, satisfactory vulvar and vaginal conformations, and apparently normal uterine and ovarian conformations were placed into a pool of potential candidates for treatment. Most of the mares were between 11 and 14 years of age (range: 8 to 22 years) and weighed 400 to 650 kg.
- SAIB diluting solvent compositions were: 75:25 w/w SAIB:DMSO in Formulation 1 (see example 1 A); 85:15 w/w SAIB:Ethanol in Formulation 2 (see example IB); and 75:25 w/w SAIB:Ethanol in Formulation 3 (see example 1C);.
- Resultant experimental formulations were hydrophobic low viscosity after i.m.
- Progesterone was measured by radioimmunoassay with commercially available reagents (Diagnostic Systems Laboratories, Inc., Webster, TX) and LH was measured by radioimmunoassay as described by Thompson et al. 1983. J. Anim. Sci. 56:678-686.
- the deslorelin was radioiodinated by the chloramine-T method and isolated by QAE-Sephadex chromatography as described for GnRH by Nett et al, Endocrinology 101 :1135 (1977). Because endogenous GnRH is not present in sufficient quantities in jugular blood for detection, any immunoreactivity in the samples was assumed to be deslorelin and not GnRH.
- results showed that plasma DA (deslorelin acetate) concentrations were significantly increased after treatment in all three SAIB formulations with peak levels of 1902 to 1699 pg/ml.
- Area under the response curve (AUC) for the first 24 hours after injection also confirmed significant increase in SAIB treated mares compared to saline treated controls (See Table II).
- Treatments were 2 experimental formulation groups containing : 0.5, 1.0, 1.5 or 2.0 mg deslorelin acetate (DA) designed to deliver DA at differing rates for approximately 12 to 36 hours (h) after a 1ml intramuscular (i.m.) injection using a 21 gauge needle; and a negative control consisting of SAIB containing no drug which was also administered as a 1ml i.m. injection.
- DA deslorelin acetate
- SAIB SAIB
- SAIB diluting solvent compositions were: 75:25 w/w SAIB:Ethanol in Formulations 4-8 (see example ID) and 65:35 w/w SAIB:Ethanol in Formulations 9-12 (see example IE).
- Estrus mares' ovaries were examined daily by ultrasound (US) and were treated once a follicle between 30mm and 40mm was detected. Thereafter, mares' ovaries were examined every 24 h until ovulation which was confirmed by US.
- US ultrasound
- the two major efficacy variables in the study were (a) interval in hours from treatment to ovulation, and (b) the percent of mares ovulating within 48 hours of treatment.
- the former was statistically analyzed using SAS® Cox's regression model (proportional hazards).
- the later was statistically analyzed using logistic regression investigating the effects of formulation and dose.
- the major safety variables in the study were (a) visible signs of swelling scores (b) sensitivity to touch, and (c) skin temperature elevation at the injection site. These variables were to be statistically analyzed by repeated measures analysis for categorical data using SAS PROC CATMOD, however, because no swelling, sensitivity or temperature elevations were detected the analysis was not performed.
- Quadratic terms were not significant for either analysis indicating that the linear models used provided a sufficient representation for all nine groups. Predicted percentage of mares ovulating by 48 hours using both types of analysis are presented in table III in parenthesis next to the actual observed data.
- ovariectomized gilts approximately 200 days old and weighing about 100 kg were used. All gilts were ovariectomized for 15 to 30 days prior to entrance to the study. Prior to treatment, all gilts received estradiol benzoate at a dosage of 15 ⁇ g/kg. Forty eight hours after estradiol benzoate treatment, gilts were challenged with the deslorelin treatment. Treatments were designed to deliver DA for approximately 6 to 12 hours after i.m. injection of 0.5, 1, 2, or 4 mis delivering 12.5, 25, 50, or 100 ⁇ g, respectively. A control group (0 ⁇ g of DA) received 1 ml of the SAIB: propylene carbonate vehicle. Both treatment and control formulations were sterilized using gamma radiation.
- Cannulas were placed non-surgically into a jugular vein 24 hours prior to deslorelin treatment, and samples collected at 0, 0.5, 1, 2, 4, 6, 12, 18, 24, 30, 36, 42, and 48 hours after deslorelin treatment to determine the LH concentrations. Samples taken at 0, 0.5, 1, 2, 4, 6, 12, 18, 24, and 30 hours were used to determine DA concentrations. The levels of these compounds was determined by radioimmunoassay, and are provided graphically in Figures 2 (DA levels) and 3 (LH levels).
- Experimental formulations were prepared by weighing and mixing SAIB, solvent and deslorelin acetate (DA) to give a final concentration of 25 ⁇ g/ml.
- the SAIB: diluting solvent composition was: SAIB/propylene carbonate 70:30 w/w).
- Experimental DA Treatments were sterilized using gamma radiation. 30 healthy cyclic dairy heifers weighing about 750-800 lbs (340-364 kg ) were used. This study was designed as a parallel group design.
- All heifers were synchronized using pretreatment with 100 ⁇ g GnRH (Cystorellin, Merial, Ltd., Islin, NJ) on day -7 followed by 25 mg PGF 2 ⁇ (Lutalyse Pharmacia-Upjohn Co. Kalamazoo, MI) treatment one week later .
- PGF 2 ⁇ Litalyse Pharmacia-Upjohn Co. Kalamazoo, MI
- Forty eight hours after PGF 2 ⁇ treatment heifers received saline (negative controls), Cystorellin (100 mg; positive controls) or Deslorelin-SABER (DA-slow delivery preparation; at 12.5, 25, 50 or 100 ⁇ g intra-muscular).
- AUC area under the curve
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
Cette invention se rapporte à une composition liquide servant à la libération régulée de l'hormone de libération de la gonadotrophine (GnRH) ou ses analogues ou agonistes, cette composition contenant: (i) une substance excipient liquide non hydrosoluble et non polymère (HVLCM) ayant une viscosité d'au moins 5000 cP à 37 °C, qui ne se cristallise pas de façon nette dans des conditions ambiantes ou physiologiques; et (ii) l'hormone GnRH ou des analogues ou agonistes de celle-ci. Cette composition peut être utilisée pour traiter des états reproductifs et/ou induire l'ovulation chez des animaux, tels que le bétail, le poisson et les crustacés.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU50253/00A AU5025300A (en) | 1999-06-18 | 2000-05-18 | Compositions for controlled release of the hormone gnrh and its analogs |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33632899A | 1999-06-18 | 1999-06-18 | |
US09/336,328 | 1999-06-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000078335A1 true WO2000078335A1 (fr) | 2000-12-28 |
Family
ID=23315592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/013615 WO2000078335A1 (fr) | 1999-06-18 | 2000-05-18 | Compositions pour la liberation regulee de l'hormone gnrh et ses analogues |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU5025300A (fr) |
WO (1) | WO2000078335A1 (fr) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001015734A3 (fr) * | 1999-08-27 | 2001-09-13 | Southern Biosystems Inc | Systeme de distribution controlee de liquide hautement visqueux et dispositif medical ou chirurgical |
WO2001078683A3 (fr) * | 2000-04-19 | 2002-05-30 | Genentech Inc | Formulations a liberation lente |
WO2003000282A1 (fr) * | 2001-06-21 | 2003-01-03 | Genentech, Inc. | Formulation a liberation lente |
WO2002028405A3 (fr) * | 2000-10-05 | 2003-05-08 | Veyx Pharma Gmbh | Procede pour determiner le debut du cycle chez des animaux d'elevage de sexe feminin |
US7824700B2 (en) | 2001-02-23 | 2010-11-02 | Genentech, Inc. | Erodible polymers for injection |
US7833543B2 (en) | 1995-06-07 | 2010-11-16 | Durect Corporation | High viscosity liquid controlled delivery system and medical or surgical device |
US8530419B2 (en) | 2003-10-03 | 2013-09-10 | Thorn Bioscience Llc | Process for the synchronization of ovulation for timed breeding without heat detection |
US8846072B2 (en) | 2004-09-17 | 2014-09-30 | Durect Corporation | Controlled delivery system |
US8905913B2 (en) | 2009-04-23 | 2014-12-09 | Jbs United Animal Health Ii Llc | Method and composition for synchronizing time of insemination |
US8945614B2 (en) | 2002-12-13 | 2015-02-03 | Durect Corporation | Oral drug delivery system |
US8956644B2 (en) | 2006-11-03 | 2015-02-17 | Durect Corporation | Transdermal delivery systems |
US9555113B2 (en) | 2013-03-15 | 2017-01-31 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
US9592204B2 (en) | 2007-12-06 | 2017-03-14 | Durect Corporation | Oral pharmaceutical dosage forms |
US9616055B2 (en) | 2008-11-03 | 2017-04-11 | Durect Corporation | Oral pharmaceutical dosage forms |
US9724380B2 (en) | 2012-11-28 | 2017-08-08 | Jbs United Animal Health Ii Llc | Method and compositions for synchronizing time of insemination in gilts |
US10471002B2 (en) | 2002-06-25 | 2019-11-12 | Durect Corporation | Short duration depot formulations |
EP3746074A1 (fr) * | 2018-01-30 | 2020-12-09 | Ceva Sante Animale | Composition antiprolactinique vétérinaire |
US11083796B2 (en) | 2005-07-26 | 2021-08-10 | Durect Corporation | Peroxide removal from drug delivery vehicle |
US11400019B2 (en) | 2020-01-13 | 2022-08-02 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
US12274794B2 (en) | 2016-07-06 | 2025-04-15 | Orient Pharma Co., Ltd. | Oral dosage form with drug composition, barrier layer and drug layer |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998053837A1 (fr) * | 1997-05-28 | 1998-12-03 | Southern Biosystems, Inc. | Composition assurant la liberation regulee de l'hormone gnrh et de ses analogues |
-
2000
- 2000-05-18 WO PCT/US2000/013615 patent/WO2000078335A1/fr active Application Filing
- 2000-05-18 AU AU50253/00A patent/AU5025300A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998053837A1 (fr) * | 1997-05-28 | 1998-12-03 | Southern Biosystems, Inc. | Composition assurant la liberation regulee de l'hormone gnrh et de ses analogues |
Non-Patent Citations (1)
Title |
---|
BARB, R. ET AL: "Evaluation of the SABER delivery system for the controlled release of deslorelin: effect of dose in estrogen primed ovariectomized gilts", PROCEEDINGS OF THE 26TH INTERNATIONAL SYMPOSIUM ON THE CONTROLLED RELEASE OF BIOACTIVE MATERIALS, 20 June 1999 (1999-06-20) - 25 June 1999 (1999-06-25), ISSN: 1022-0178, pages 1170 - 1171, XP002149549 * |
Cited By (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7833543B2 (en) | 1995-06-07 | 2010-11-16 | Durect Corporation | High viscosity liquid controlled delivery system and medical or surgical device |
US6413536B1 (en) | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
WO2001015734A3 (fr) * | 1999-08-27 | 2001-09-13 | Southern Biosystems Inc | Systeme de distribution controlee de liquide hautement visqueux et dispositif medical ou chirurgical |
WO2001078683A3 (fr) * | 2000-04-19 | 2002-05-30 | Genentech Inc | Formulations a liberation lente |
US6992065B2 (en) | 2000-04-19 | 2006-01-31 | Genentech, Inc. | Sustained release formulations |
WO2002028405A3 (fr) * | 2000-10-05 | 2003-05-08 | Veyx Pharma Gmbh | Procede pour determiner le debut du cycle chez des animaux d'elevage de sexe feminin |
US8501216B2 (en) | 2001-02-23 | 2013-08-06 | Genentech, Inc. | Bioerodible polymers for injection |
US7824700B2 (en) | 2001-02-23 | 2010-11-02 | Genentech, Inc. | Erodible polymers for injection |
US7318931B2 (en) | 2001-06-21 | 2008-01-15 | Genentech, Inc. | Sustained release formulation |
US8067020B2 (en) | 2001-06-21 | 2011-11-29 | Genetech, Inc. | Sustained release formulation |
WO2003000282A1 (fr) * | 2001-06-21 | 2003-01-03 | Genentech, Inc. | Formulation a liberation lente |
US11179326B2 (en) | 2002-06-25 | 2021-11-23 | Durect Corporation | Short duration depot formulations |
US10471002B2 (en) | 2002-06-25 | 2019-11-12 | Durect Corporation | Short duration depot formulations |
US10471001B2 (en) | 2002-06-25 | 2019-11-12 | Durect Corporation | Short duration depot formulations |
US8974821B2 (en) | 2002-12-13 | 2015-03-10 | Durect Corporation | Oral drug delivery system |
US9517271B2 (en) | 2002-12-13 | 2016-12-13 | Durect Corporation | Oral drug delivery system |
US9918982B2 (en) | 2002-12-13 | 2018-03-20 | Durect Corporation | Oral drug delivery system |
US8945614B2 (en) | 2002-12-13 | 2015-02-03 | Durect Corporation | Oral drug delivery system |
US8951556B2 (en) | 2002-12-13 | 2015-02-10 | Durect Corporation | Oral drug delivery system |
US9233160B2 (en) | 2002-12-13 | 2016-01-12 | Durect Corporation | Oral drug delivery system |
US8937044B2 (en) | 2003-10-03 | 2015-01-20 | Thorn Bioscience Llc | Process for the synchronization of ovulation for timed breeding without heat detection |
US20140155327A1 (en) * | 2003-10-03 | 2014-06-05 | Thorn Bioscience Llc | Process for the Synchronization of Ovulation for Timed Breeding Without Heat Detection |
US10028996B2 (en) | 2003-10-03 | 2018-07-24 | Thorn Bioscience Llc | Process for the synchronization of ovulation for timed breeding without heat detection |
US9351818B2 (en) | 2003-10-03 | 2016-05-31 | Thorn Bioscience Llc | Process for the synchronization of ovulation for timed breeding without heat detection |
US9018165B2 (en) * | 2003-10-03 | 2015-04-28 | Thorn Bioscience Llc | Process for the synchronization of ovulation for timed breeding without heat detection |
US8927496B2 (en) | 2003-10-03 | 2015-01-06 | Thorn Bioscience Llc | Process for the synchronization of ovulation for timed breeding without heat detection |
US10898539B2 (en) | 2003-10-03 | 2021-01-26 | Thorn BioSciences LLC | Process for the synchronization of ovulation for timed breeding without heat detection |
US8530419B2 (en) | 2003-10-03 | 2013-09-10 | Thorn Bioscience Llc | Process for the synchronization of ovulation for timed breeding without heat detection |
US8846072B2 (en) | 2004-09-17 | 2014-09-30 | Durect Corporation | Controlled delivery system |
US11083796B2 (en) | 2005-07-26 | 2021-08-10 | Durect Corporation | Peroxide removal from drug delivery vehicle |
US8956644B2 (en) | 2006-11-03 | 2015-02-17 | Durect Corporation | Transdermal delivery systems |
US9655861B2 (en) | 2007-12-06 | 2017-05-23 | Durect Corporation | Oral pharmaceutical dosage forms |
US9592204B2 (en) | 2007-12-06 | 2017-03-14 | Durect Corporation | Oral pharmaceutical dosage forms |
US10206883B2 (en) | 2007-12-06 | 2019-02-19 | Durect Corporation | Oral pharamaceutical dosage forms |
US10328068B2 (en) | 2008-11-03 | 2019-06-25 | Durect Corporation | Oral pharmaceutical dosage forms |
US9884056B2 (en) | 2008-11-03 | 2018-02-06 | Durect Corporation | Oral pharmaceutical dosage forms |
US9616055B2 (en) | 2008-11-03 | 2017-04-11 | Durect Corporation | Oral pharmaceutical dosage forms |
US10668127B2 (en) | 2009-04-23 | 2020-06-02 | United-Ah Ii, Llc | Method and composition for synchronizing time of insemination |
US8905913B2 (en) | 2009-04-23 | 2014-12-09 | Jbs United Animal Health Ii Llc | Method and composition for synchronizing time of insemination |
US9757425B2 (en) | 2009-04-23 | 2017-09-12 | Jbs United Animal Health Ii Llc | Method and composition for synchronizing time of insemination |
US9352011B2 (en) | 2009-04-23 | 2016-05-31 | Jbs United Animal Health Ii Llc | Method and composition for synchronizing time of insemination |
US9724380B2 (en) | 2012-11-28 | 2017-08-08 | Jbs United Animal Health Ii Llc | Method and compositions for synchronizing time of insemination in gilts |
US10376558B2 (en) | 2012-11-28 | 2019-08-13 | United-Ah Ii, Llc | Method and compositions for synchronizing time of insemination in gilts |
US10300142B2 (en) | 2013-03-15 | 2019-05-28 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
US9572885B2 (en) | 2013-03-15 | 2017-02-21 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
US9555113B2 (en) | 2013-03-15 | 2017-01-31 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
US9907851B2 (en) | 2013-03-15 | 2018-03-06 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
US9855333B2 (en) | 2013-03-15 | 2018-01-02 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
US12274794B2 (en) | 2016-07-06 | 2025-04-15 | Orient Pharma Co., Ltd. | Oral dosage form with drug composition, barrier layer and drug layer |
EP3746074A1 (fr) * | 2018-01-30 | 2020-12-09 | Ceva Sante Animale | Composition antiprolactinique vétérinaire |
US11400019B2 (en) | 2020-01-13 | 2022-08-02 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
US11771624B2 (en) | 2020-01-13 | 2023-10-03 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
Also Published As
Publication number | Publication date |
---|---|
AU5025300A (en) | 2001-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1017411B1 (fr) | Composition assurant la liberation regulee de l'hormone gnrh et de ses analogues | |
WO2000078335A1 (fr) | Compositions pour la liberation regulee de l'hormone gnrh et ses analogues | |
Armstrong et al. | Endocrine responses of goats after induction of superovulation with PMSG and FSH | |
Junaidi et al. | Use of a new drug delivery formulation of the gonadotrophin-releasing hormone analogue Deslorelin for reversible long-term contraception in male dogs | |
KR20010034494A (ko) | 길트의 발정기 및 배란의 조절 | |
Donaldson et al. | Luteotropic properties of luteinizing hormone and nature of oxytocin induced luteal inhibition in cattle | |
US20200376002A1 (en) | Injectable Hormone Formulations for Estrous Cycle Control in Mammals, its Manufacturing Process, Estrous Cycle Control and Puberty Triggering Methods, and Pregnancy Enhancement in Mammals | |
US20090036384A1 (en) | Increasing pregnancy rates | |
Gallab et al. | Maximizing the reproductive performances of anestrus dairy buffalo cows using GnRH analogue-loaded chitosan nanoparticles during the low breeding season | |
Horta et al. | Possibility of reducing the luteolytic dose of cloprostenol in cyclic dairy cows | |
Blanchard et al. | Regulation of estrus and ovulation in mares with progesterone or progesterone and estradiol biodegradable microspheres with or without PGF2α | |
US20060025328A1 (en) | Compositions suitable for controlled release of the hormone GnRH and its analogs | |
Williams et al. | Continuous administration of low-dose GnRH in mares: I. Control of persistent anovulation during the ovulatory season | |
Ronayne et al. | Effect of immunization of ewes against prostaglandin F-2α on the life-span of corpora lutea and oestrous behaviour during two breeding seasons | |
Thorson et al. | Pharmacologic application of native GnRH in the winter anovulatory mare, I: Frequency of reversion to the anovulatory state following ovulation induction and cessation of treatment | |
O'Neil et al. | Differential regulation of gonadotropins in response to continuous infusion of native gonadotropin-releasing hormone in the winter anovulatory mare and effects of treatment with estradiol-17β | |
Prestel et al. | Suppression of reproductive function in juvenile rams by a slow-release gonadotropin-releasing hormone implant | |
MXPA99010936A (en) | Compositions suitable for controlled release of the hormone gnrh and its analogs | |
NL9301762A (nl) | Farmaceutische preparaten die altrenogest bevatten. | |
Ghadery et al. | Estradiol benzoate priming during induction of estrus with Vitex-castus extract in dogs | |
Burns et al. | Evaluation of the saber™ delivery system for the controlled release of deslorelin acetate for advancing ovulation in the mare: Effects of formulation & dose | |
Martinez | Synchronization of follicular wave dynamics and ovulation for fixed-time artificial insemination in cattle | |
Hori et al. | Effects of administration of prostagrandin F2α-analogue fenprostalene on canine corpus luteum and subsequent recurrence of estrus and fecundity | |
Fleury et al. | Regulation of estrus and ovulation in cyclic mares with progesterone and estradiol biodegradable microspheres: effects of different doses of estradiol | |
Türkoğlu et al. | The Effect of Subcutaneously Administered Crystal's Oily Solution on Estrus and Conception Rates in Ewes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN JP MX |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |